Skip to Content
Is your type 2 diabetes treatment the right match?

Ranibizumab ophthalmic Pregnancy and Breastfeeding Warnings

Ranibizumab ophthalmic is also known as: Lucentis

Ranibizumab ophthalmic Pregnancy Warnings

Ranibizumab has been assigned to pregnancy category C by the FDA. Animal studies have demonstrated skeletal abnormalities in fetuses with trough exposures up to 13 times higher than predicted Cmax levels with a single eye treatment in humans, but these abnormalities were not seen at doses which resulted in trough exposures equivalent to a single eye treatment in humans. It is not known whether ranibizumab administered to a pregnant woman can cause fetal harm or affect reproduction. There are no controlled data in human pregnancy. Since ranibizumab may pose a risk to embryo-fetal development and reproductive capacity, it should be given during pregnancy when need has been clearly established.

See references

Ranibizumab ophthalmic Breastfeeding Warnings

There are no data on the excretion of ranibizumab into human milk. Because many drugs are excreted in human milk, and because the potential for absorption and harm to infant growth and development exists, caution is recommended if ranibizumab is administered to a nursing woman.

See references

References for pregnancy information

  1. "Product Information. Lucentis (ranibizumab ophthalmic)." Genentech, South San Francisco, CA.

References for breastfeeding information

  1. "Product Information. Lucentis (ranibizumab ophthalmic)." Genentech, South San Francisco, CA.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.